These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 7793137)

  • 1. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
    Hancock GE; Speelman DJ; Frenchick PJ; Mineo-Kuhn MM; Baggs RB; Hahn DJ
    Vaccine; 1995 Mar; 13(4):391-400. PubMed ID: 7793137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.
    Hancock GE; Speelman DJ; Heers K; Bortell E; Smith J; Cosco C
    J Virol; 1996 Nov; 70(11):7783-91. PubMed ID: 8892899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus.
    Hancock GE; Hahn DJ; Speelman DJ; Hildreth SW; Pillai S; McQueen K
    Vaccine; 1994; 12(3):267-74. PubMed ID: 8165859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.
    Hancock GE; Smith JD; Heers KM
    Viral Immunol; 2000; 13(1):57-72. PubMed ID: 10733169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QS-21 synergizes with recombinant interleukin-12 to create a potent adjuvant formulation for the fusion protein of respiratory syncytial virus.
    Hancock GE; Heers KM; Smith JD
    Viral Immunol; 2000; 13(4):503-9. PubMed ID: 11192297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).
    Hancock GE; Heers KM; Smith JD; Scheuer CA; Ibraghimov AR; Pryharski KS
    Vaccine; 2001 Sep; 19(32):4874-82. PubMed ID: 11535341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.
    Tebbey PW; Scheuer CA; Peek JA; Zhu D; LaPierre NA; Green BA; Phillips ED; Ibraghimov AR; Eldridge JH; Hancock GE
    Vaccine; 2000 Jun; 18(24):2723-34. PubMed ID: 10781860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity.
    Garg R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    J Gen Virol; 2014 May; 95(Pt 5):1043-1054. PubMed ID: 24572813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
    McGinnes Cullen L; Schmidt MR; Morrison TG
    J Virol; 2019 May; 93(9):. PubMed ID: 30760576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles.
    Jiang B; Estes MK; Barone C; Barniak V; O'Neal CM; Ottaiano A; Madore HP; Conner ME
    Vaccine; 1999 Feb; 17(7-8):1005-13. PubMed ID: 10067709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.
    Goetsch L; Plotnicky-Gilquin H; Champion T; Beck A; Corvaïa N; Stâhl S; Bonnefoy JY; Nguyen TN; Power UF
    Vaccine; 2000 Jun; 18(24):2735-42. PubMed ID: 10781861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
    Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
    Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.